EU inches closer to new pharma legislation amid competitiveness drive
Pharmaceutical companies marketing products in Europe could be set for a commercial boost, after legislators have agreed on a new…
12 Dec 2025
China’s NMPA approves Sanofi’s rare haematologic disease treatments
China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease treatments, Qfitlia (fitusiran) and Cablivi (caplacizumab), for patients with haemophilia and acquired thrombotic thrombocytopenic purpura (aTTP)…
12 Dec 2025
Zealand Pharma and OTR to develop metabolic disease therapeutics
Zealand Pharma and OTR Therapeutics have signed a strategic collaboration and licence agreement aimed at jointly discovering and developing therapies for several targets in metabolic diseases. The multi-programme partnership leverages…
11 Dec 2025
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn
Novartis has teamed up with AI-led biotech Relation Therapeutics in a deal worth up to approximately $1.7bn to discover and develop novel targets for atopic diseases. Through the agreement, the…
11 Dec 2025
Moderna signs deal worth up to $503m with Nanexa
Moderna has entered a licence agreement with Nanexa to add tailored release profiles to its injectable drugs. According to the contract, Moderna will pay $3m upfront to Nanexa to use…
11 Dec 2025
UK slashes 2026 drug rebate rate by one-third to win back pharma sentiments
The UK Government has cut its innovative medicine rebate rate by more than a third in a move likely to be welcomed by the pharma industry. This means pharma companies…
11 Dec 2025
Pfizer plans job cuts in Switzerland to reduce expenses
Pfizer is set to cut jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg. According to information not yet made public, the company…